Profile data is unavailable for this security.
About the company
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
- Revenue in USD (TTM)631.56k
- Net income in USD-32.50m
- Incorporated2014
- Employees25.00
- LocationOvid Therapeutics Inc441 NINTH AVENUE, 14TH FLOORNEW YORK 10001United StatesUSA
- Phone+1 (212) 776-4381
- Fax+1 (302) 636-5454
- Websitehttps://ovidrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beyondspring Inc | 1.88m | -15.57m | 68.91m | 35.00 | -- | -- | -- | 36.73 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 70.59m | -- | 4.09 | 0.1428 | 36.51 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Bioatla Inc | 11.00m | -81.82m | 71.55m | 65.00 | -- | 3.12 | -- | 6.50 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Vistagen Therapeutics Inc | 875.70k | -39.57m | 72.67m | 45.00 | -- | 0.7595 | -- | 82.99 | -1.30 | -1.30 | 0.0289 | 3.44 | 0.0121 | -- | -- | 22,453.85 | -54.69 | -62.84 | -58.94 | -68.03 | -- | -- | -4,518.12 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| P3 Health Partners Inc | 1.48bn | -102.69m | 72.90m | 400.00 | -- | 0.2739 | -- | 0.0494 | -0.753 | -0.753 | 11.08 | 0.744 | 1.71 | -- | 12.28 | 3,691,575.00 | -28.94 | -- | -83.29 | -- | -2.72 | 0.1781 | -16.95 | -56.93 | -- | -12.94 | 0.3358 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 73.08m | 45.00 | -- | 0.8022 | -- | 21.58 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Ovid Therapeutics Inc | 631.56k | -32.50m | 73.81m | 25.00 | -- | 0.968 | -- | 116.87 | -0.4598 | -0.4598 | 0.0089 | 1.07 | 0.0056 | -- | -- | 15,789.00 | -28.55 | -20.78 | -31.34 | -23.27 | -- | -- | -5,146.15 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 74.17m | 12.00 | -- | 9.02 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.56m | 74.56m | 25.00 | -- | 3.39 | -- | -- | -1.17 | -1.17 | 0.00 | 0.5975 | 0.00 | -- | -- | 0.00 | -73.98 | -51.63 | -98.74 | -59.00 | -- | -- | -- | -- | -- | -19.13 | 0.5286 | -- | -- | -- | -5.11 | -- | -- | -- |
| VolitionRX Ltd | 1.29m | -29.87m | 74.60m | 110.00 | -- | -- | -- | 58.02 | -0.3623 | -0.3623 | 0.0155 | -0.2328 | 0.0837 | -- | 7.41 | 11,689.36 | -196.61 | -111.92 | -- | -196.20 | -- | -- | -2,348.71 | -10,793.31 | -- | -104.15 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Armata Pharmaceuticals Inc | 5.47m | -41.36m | 75.62m | 66.00 | -- | -- | -- | 13.83 | -1.24 | -1.24 | 0.1312 | -1.41 | 0.0518 | -- | 1.02 | 82,833.34 | -39.21 | -59.78 | -116.66 | -72.70 | -- | -- | -756.59 | -1,113.72 | -- | -- | 1.90 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Aerovate Therapeutics Inc | 0.00 | -84.61m | 76.79m | 51.00 | -- | 0.954 | -- | -- | -2.99 | -2.99 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -72.99 | -- | -81.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 76.79m | 50.00 | -- | 0.5957 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -17.78m | 77.64m | 10.00 | -- | 27.76 | -- | -- | -0.8864 | -0.8864 | 0.00 | 0.0807 | 0.00 | -- | -- | 0.00 | -149.60 | -- | -225.38 | -- | -- | -- | -- | -- | -- | -- | 0.0403 | -- | -- | -- | -272.15 | -- | -- | -- |
| Chimerix Inc | 159.00k | -83.59m | 79.14m | 72.00 | -- | 0.5829 | -- | 497.76 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
Data as of Nov 21 2024. Currency figures normalised to Ovid Therapeutics Inc's reporting currency: US Dollar USD
39.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 30 Sep 2024 | 5.32m | 7.49% |
| Madison Avenue Partners LPas of 30 Sep 2024 | 4.12m | 5.80% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.99m | 5.62% |
| BVF Partners LPas of 30 Sep 2024 | 3.85m | 5.43% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.02m | 4.26% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 1.85m | 2.60% |
| Kennedy Capital Management LLCas of 30 Sep 2024 | 1.53m | 2.15% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 1.40m | 1.97% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.36m | 1.92% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.32m | 1.86% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
